Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) Equity Average (2016 - 2025)

Traws Pharma's Equity Average history spans 14 years, with the latest figure at $2.0 million for Q4 2025.

  • Quarterly results put Equity Average at $2.0 million for Q4 2025, up 111.63% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (up 111.63% YoY), and the annual figure for FY2025 was -$16.1 million, down 53.92%.
  • Equity Average for Q4 2025 was $2.0 million at Traws Pharma, down from $6.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $47.9 million in Q4 2021 to a low of -$53.8 million in Q3 2024.
  • The 5-year median for Equity Average is $18.8 million (2023), against an average of $13.2 million.
  • The sharpest move saw Equity Average soared 420.86% in 2021, then plummeted 421.87% in 2024.
  • Year by year, Equity Average stood at $47.9 million in 2021, then tumbled by 35.61% to $30.8 million in 2022, then crashed by 59.16% to $12.6 million in 2023, then crashed by 233.64% to -$16.8 million in 2024, then soared by 111.63% to $2.0 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $2.0 million, $6.4 million, and $7.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.